FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804599930> ?p ?o ?g. }

• W2804599930 endingPage "10343" @default.
• W2804599930 startingPage "10333" @default.
• W2804599930 abstract "Peroxisome proliferator–activated receptor α (PPARα) is a ligand-activated transcription factor that belongs to the superfamily of nuclear hormone receptors. PPARα is mainly expressed in the liver, where it activates fatty acid oxidation and lipoprotein metabolism and improves plasma lipid profiles. Therefore, PPARα activators are often used to treat patients with dyslipidemia. To discover additional PPARα activators as potential compounds for use in hypolipidemic drugs, here we established human hepatoblastoma cell lines with luciferase reporter expression from the promoters containing peroxisome proliferator–responsive elements (PPREs) and tetracycline-regulated expression of full-length human PPARα to quantify the effects of chemical ligands on PPARα activity. Using the established cell-based PPARα-activator screening system to screen a library of >12,000 chemical compounds, we identified several hit compounds with basic chemical skeletons different from those of known PPARα agonists. One of the hit compounds, a 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivative we termed compound 3, selectively up-regulated PPARα transcriptional activity, leading to PPARα target gene expression both in vitro and in vivo. Of note, the half-maximal effective concentrations of the hit compounds were lower than that of the known PPARα ligand fenofibrate. Finally, fenofibrate or compound 3 treatment of high fructose–fed rats having elevated plasma triglyceride levels for 14 days indicated that compound 3 reduces plasma triglyceride levels with similar efficiency as fenofibrate. These observations raise the possibility that 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives might be effective drug candidates for selective targeting of PPARα to manage dyslipidemia. Peroxisome proliferator–activated receptor α (PPARα) is a ligand-activated transcription factor that belongs to the superfamily of nuclear hormone receptors. PPARα is mainly expressed in the liver, where it activates fatty acid oxidation and lipoprotein metabolism and improves plasma lipid profiles. Therefore, PPARα activators are often used to treat patients with dyslipidemia. To discover additional PPARα activators as potential compounds for use in hypolipidemic drugs, here we established human hepatoblastoma cell lines with luciferase reporter expression from the promoters containing peroxisome proliferator–responsive elements (PPREs) and tetracycline-regulated expression of full-length human PPARα to quantify the effects of chemical ligands on PPARα activity. Using the established cell-based PPARα-activator screening system to screen a library of >12,000 chemical compounds, we identified several hit compounds with basic chemical skeletons different from those of known PPARα agonists. One of the hit compounds, a 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivative we termed compound 3, selectively up-regulated PPARα transcriptional activity, leading to PPARα target gene expression both in vitro and in vivo. Of note, the half-maximal effective concentrations of the hit compounds were lower than that of the known PPARα ligand fenofibrate. Finally, fenofibrate or compound 3 treatment of high fructose–fed rats having elevated plasma triglyceride levels for 14 days indicated that compound 3 reduces plasma triglyceride levels with similar efficiency as fenofibrate. These observations raise the possibility that 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives might be effective drug candidates for selective targeting of PPARα to manage dyslipidemia." @default.
• W2804599930 created "2018-06-01" @default.
• W2804599930 creator A5000509868 @default.
• W2804599930 creator A5002421342 @default.
• W2804599930 creator A5011433902 @default.
• W2804599930 creator A5014010927 @default.
• W2804599930 creator A5014464488 @default.
• W2804599930 creator A5019269482 @default.
• W2804599930 creator A5022142360 @default.
• W2804599930 creator A5032395824 @default.
• W2804599930 creator A5041382010 @default.
• W2804599930 creator A5042225927 @default.
• W2804599930 creator A5042830645 @default.
• W2804599930 creator A5062302270 @default.
• W2804599930 creator A5071033580 @default.
• W2804599930 creator A5071094094 @default.
• W2804599930 creator A5082083875 @default.
• W2804599930 creator A5086288542 @default.
• W2804599930 creator A5086668054 @default.
• W2804599930 creator A5087837717 @default.
• W2804599930 creator A5091906677 @default.
• W2804599930 date "2018-06-01" @default.
• W2804599930 modified "2023-10-15" @default.
• W2804599930 title "Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line" @default.
• W2804599930 cites W1548019355 @default.
• W2804599930 cites W1615613652 @default.
• W2804599930 cites W1963533730 @default.
• W2804599930 cites W1966282566 @default.
• W2804599930 cites W1967374891 @default.
• W2804599930 cites W1969115817 @default.
• W2804599930 cites W1974139741 @default.
• W2804599930 cites W1974658675 @default.
• W2804599930 cites W1975062798 @default.
• W2804599930 cites W1977162423 @default.
• W2804599930 cites W1982027543 @default.
• W2804599930 cites W1994763926 @default.
• W2804599930 cites W2000566048 @default.
• W2804599930 cites W2006574739 @default.
• W2804599930 cites W2019542803 @default.
• W2804599930 cites W2022684565 @default.
• W2804599930 cites W2045383586 @default.
• W2804599930 cites W2061357909 @default.
• W2804599930 cites W2064951395 @default.
• W2804599930 cites W2072362233 @default.
• W2804599930 cites W2080361134 @default.
• W2804599930 cites W2090429649 @default.
• W2804599930 cites W2105259330 @default.
• W2804599930 cites W2111016870 @default.
• W2804599930 cites W2121914083 @default.
• W2804599930 cites W2121960517 @default.
• W2804599930 cites W2132196134 @default.
• W2804599930 cites W2141726002 @default.
• W2804599930 cites W2144259092 @default.
• W2804599930 cites W2149044745 @default.
• W2804599930 cites W2165610631 @default.
• W2804599930 cites W2172256092 @default.
• W2804599930 cites W2212640525 @default.
• W2804599930 cites W2299484714 @default.
• W2804599930 cites W2401868452 @default.
• W2804599930 cites W2602059628 @default.
• W2804599930 cites W98247596 @default.
• W2804599930 doi "https://doi.org/10.1074/jbc.ra118.002077" @default.
• W2804599930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6028958" @default.
• W2804599930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29764933" @default.
• W2804599930 hasPublicationYear "2018" @default.
• W2804599930 type Work @default.
• W2804599930 sameAs 2804599930 @default.
• W2804599930 citedByCount "10" @default.
• W2804599930 countsByYear W28045999302019 @default.
• W2804599930 countsByYear W28045999302020 @default.
• W2804599930 countsByYear W28045999302021 @default.
• W2804599930 countsByYear W28045999302022 @default.
• W2804599930 crossrefType "journal-article" @default.
• W2804599930 hasAuthorship W2804599930A5000509868 @default.
• W2804599930 hasAuthorship W2804599930A5002421342 @default.
• W2804599930 hasAuthorship W2804599930A5011433902 @default.
• W2804599930 hasAuthorship W2804599930A5014010927 @default.
• W2804599930 hasAuthorship W2804599930A5014464488 @default.
• W2804599930 hasAuthorship W2804599930A5019269482 @default.
• W2804599930 hasAuthorship W2804599930A5022142360 @default.
• W2804599930 hasAuthorship W2804599930A5032395824 @default.
• W2804599930 hasAuthorship W2804599930A5041382010 @default.
• W2804599930 hasAuthorship W2804599930A5042225927 @default.
• W2804599930 hasAuthorship W2804599930A5042830645 @default.
• W2804599930 hasAuthorship W2804599930A5062302270 @default.
• W2804599930 hasAuthorship W2804599930A5071033580 @default.
• W2804599930 hasAuthorship W2804599930A5071094094 @default.
• W2804599930 hasAuthorship W2804599930A5082083875 @default.
• W2804599930 hasAuthorship W2804599930A5086288542 @default.
• W2804599930 hasAuthorship W2804599930A5086668054 @default.
• W2804599930 hasAuthorship W2804599930A5087837717 @default.
• W2804599930 hasAuthorship W2804599930A5091906677 @default.
• W2804599930 hasBestOaLocation W28045999301 @default.
• W2804599930 hasConcept C104317684 @default.
• W2804599930 hasConcept C127078168 @default.
• W2804599930 hasConcept C170493617 @default.
• W2804599930 hasConcept C185592680 @default.
• W2804599930 hasConcept C187345961 @default.

• next